arthritis of the back Spondyloarthritis
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - First degree relative of HLA-B27 positive AxSpA patients - Age between 18 and 40 years at time of inclusion - Able and willing to give written informed consent - 10 participants with an MRI highly suggestive of SpA according to the ASAS definition at baseline - 10 patients without an MRI highly suggestive of SpA according to the ASAS definition at baseline
Exclusion criteria
Exclusion criteria: - Patients already diagnosed with spondyloarthritis - Individuals with concomitant conditions which may impact participation to the study or interpretation of the data, such as: - Individuals that have an arthritic disease, other than SpA - Individuals that have a diagnosed condition with back pain other than SpA (e.g. diagnosed intervertebral disc degenration) - Individuals with communication problems - Individuals with psychiatric diseases - Individuals with drug abuse - Individuals with a life expectancy less than 5 years - Individuals who are pregnant or have a positive hcg urine test - Individuals who are breastfeeding - Individuals who have received treatment with any investigational drug within previous 3 months - Individuals who already received a research related radiation burden (cumulative > 5 mSv) in the year before inclusion - Other conditions by judgement of the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Our main endpoint is [18F]Fluoride uptake present in the sternum, spine and SI joints on whole body PET-CT scans in 10 participants with sacroiliitis on MRI and 10 participants without sacroiliitis on MRI of the Pre-Spa cohort. Both percentage of participants with any PET-positive lesion as well as dichotomous scores of lesions and cumulative scores per participant will be described. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of clinical features between individuals with [18F] PET positive lesion and those with negative [18F]PET-CT at baseline and follow up following the Pre-Spa Study protocol until five years after start of the study. Evaluate if presence of [18F]Fluoride PET-lesions is related to molecular features (e.g. gene expression or serum biomarker). | — |
Countries
Netherlands
Outcome results
None listed